Intracellular Therapies Overview
- Year Founded
-
2002

- Status
-
Public
- Employees
-
561

- Stock Symbol
-
ITCI

- Share Price
-
$127.01
- (As of Friday Closing)
Intracellular Therapies General Information
Description
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Contact Information
Website
www.intracellulartherapies.comCorporate Office
- 135 Route 202/206
- Suite 6
- Bedminster, NJ 07921
- United States
Corporate Office
- 135 Route 202/206
- Suite 6
- Bedminster, NJ 07921
- United States
Intracellular Therapies Stock Performance
As of 07-Feb-2025, Intracellular Therapies’s stock price is $127.01. Its current market cap is $13.5B with 106M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$127.01 | $127.12 | $62.78 - $128.00 | $13.5B | 106M | 2.33M | -$0.87 |
Intracellular Therapies Financials Summary
As of 30-Sep-2024, Intracellular Therapies has a trailing 12-month revenue of $613M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 6,727,030 | 6,417,029 | 4,409,462 | 3,812,909 |
Revenue | 612,784 | 462,175 | 249,132 | 81,708 |
EBITDA | (121,086) | (158,853) | (262,970) | (285,155) |
Net Income | (86,370) | (139,674) | (256,256) | (284,126) |
Total Assets | 1,324,445 | 728,295 | 754,780 | 489,922 |
Total Debt | 17,709 | 16,938 | 20,041 | 25,407 |
Intracellular Therapies Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Intracellular Therapies Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Intracellular Therapies Comparisons
Industry
Financing
Details
Intracellular Therapies Competitors (56)
One of Intracellular Therapies’s 56 competitors is Vanda Pharmaceuticals, a Formerly VC-backed company based in Washington, DC.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Vanda Pharmaceuticals | Formerly VC-backed | Washington, DC | ||||
Rigel Pharmaceuticals | Formerly VC-backed | South San Francisco, CA | ||||
Apexian Pharmaceuticals | Venture Capital-Backed | Indianapolis, IN | ||||
Cerecin | Venture Capital-Backed | Denver, CO | ||||
GT Biopharma | Corporation | Brisbane, CA |
Intracellular Therapies Patents
Intracellular Therapies Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2023320312-A1 | Novel salts and crystals | Pending | 30-Jul-2022 | ||
US-20230372336-A1 | Novel methods | Pending | 18-May-2022 | ||
US-20240122924-A1 | Novel methods | Pending | 18-May-2022 | ||
AU-2023272111-A1 | Novel methods | Pending | 18-May-2022 | ||
AU-2023236707-A1 | Organic compounds | Pending | 14-Mar-2022 | C07D471/16 |
Intracellular Therapies Signals
Intracellular Therapies ESG
Risk Overview
Risk Rating
Updated October, 15, 2024
33.93 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Pharmaceuticals
Subindustry
of 425
Rank
Percentile

Intracellular Therapies FAQs
-
When was Intracellular Therapies founded?
Intracellular Therapies was founded in 2002.
-
Where is Intracellular Therapies headquartered?
Intracellular Therapies is headquartered in Bedminster, NJ.
-
What is the size of Intracellular Therapies?
Intracellular Therapies has 561 total employees.
-
What industry is Intracellular Therapies in?
Intracellular Therapies’s primary industry is Drug Discovery.
-
Is Intracellular Therapies a private or public company?
Intracellular Therapies is a Public company.
-
What is Intracellular Therapies’s stock symbol?
The ticker symbol for Intracellular Therapies is ITCI.
-
What is the current stock price of Intracellular Therapies?
As of 07-Feb-2025 the stock price of Intracellular Therapies is $127.01.
-
What is the current market cap of Intracellular Therapies?
The current market capitalization of Intracellular Therapies is $13.5B.
-
What is Intracellular Therapies’s current revenue?
The trailing twelve month revenue for Intracellular Therapies is $613M.
-
Who are Intracellular Therapies’s competitors?
Vanda Pharmaceuticals, Rigel Pharmaceuticals, Apexian Pharmaceuticals, Cerecin, and GT Biopharma are some of the 56 competitors of Intracellular Therapies.
-
What is Intracellular Therapies’s annual earnings per share (EPS)?
Intracellular Therapies’s EPS for 12 months was -$0.87.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »